日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

CheckMate 9ER 随机 III 期试验中，对纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的最终分析

期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2025.09.006
Motzer, R J; Escudier, B; Burotto, M; Powles, T; Apolo, A B; Bourlon, M T; Shah, A Y; Porta, C; Suárez, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; Scheffold, C; Askelson, M; Panzica, J; Zhang, J; van Kooten Losio, M; Choueiri, T K
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2026
文献求助 收藏

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial

纳武利尤单抗联合吉西他滨-顺铂治疗不可切除或转移性尿路上皮癌：来自 III 期 CheckMate 901 试验的健康相关生活质量分析

期刊:ESMO Open
影响因子:
doi:10.1016/j.esmoop.2026.106089
Bedke, J; van der Heijden, M S; Sonpavde, G; Galsky, M D; Liao, W; Shi, L; Blum, S I; Mitra, S; Patel, M Y; Powles, T
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients

Avelumab一线维持治疗晚期尿路上皮癌：JAVELIN Bladder 100试验中老年患者的长期疗效

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104506
Gupta, S; Climent Duran, M A; Sridhar, S S; Powles, T; Bellmunt, J; Park, S H; Gurney, H; Tsuchiya, N; Petrylak, D P; Tomita, Y; di Pietro, A; Manitz, J; Tyroller, K; Hoffman, J; Jacob, N; Grivas, P
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study

一线晚期肾细胞癌患者的健康相关生活质量状况和临床结局：基于CheckMate 9ER研究的建模分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105115
Cella, D; Derosa, M; Floden, L; Giles, R H; Lothgren, M; Ogareva, A; Powles, T; Purnajo, I; Choueiri, T K; Bergerot, C; Motzer, R J; Bedke, J
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2025
文献求助 收藏

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma

在既往接受过恩福妥单抗治疗的转移性尿路上皮癌患者中，沙妥珠单抗戈维替康的真实世界临床疗效

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105305
Sternschuss, M; Toumbacaris, N; Das, J P; Powles, T; Kotecha, R R; Laccetti, A L; Xiao, H; Feld, E; McHugh, D J; Keegan, N M; Bajorin, D F; Funt, S A; Shah, N J; Iyer, G; Aggen, D H; Teo, M Y; Ostrovnaya, I; Rosenberg, J E
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

EV-302 的探索性亚组分析：一项评估恩福妥单抗联合帕博利珠单抗与化疗治疗既往未接受治疗的局部晚期或转移性尿路上皮癌的 III 期全球研究

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105544
van der Heijden, M S; Powles, T; Gupta, S; Loriot, Y; Galsky, M D; Valderrama, B P; Sridhar, S S; Yu, E Y; Iyer, G; Kikuchi, E; Castellano, D; Hoffman-Censits, J; Drakaki, A; Mar, N; Maroto Rey, J P; Vulsteke, C; Arafat, W; Duran, I; Dawson, N A; Swami, U; Gorla, S; Moreno, B H; Yu, X; Lu, Y-T; Bedke, J
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

纳武利尤单抗联合卡博替尼对比舒尼替尼一线治疗晚期肾细胞癌：来自 III 期随机 CheckMate 9ER 试验的延长随访结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.102994
Powles, T; Burotto, M; Escudier, B; Apolo, A B; Bourlon, M T; Shah, A Y; Suárez, C; Porta, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; George, S; Scheffold, C; Wang, P; Fedorov, V; Motzer, R J; Choueiri, T K
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2024
文献求助 收藏

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria

恩福妥单抗和帕博利珠单抗在晚期尿路上皮癌患者中的临床应用：以临床判断而非治疗标准为依据

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103725
Apolo, A B; Bellmunt, J; Cordes, L; Gupta, S; Powles, T; Rosenberg, J E; Van Der Heijden, M S
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

阿特珠单抗单药治疗转移性尿路上皮癌：II期IMvigor210试验的最终分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103972
Rosenberg, J E; Galsky, M D; Powles, T; Petrylak, D P; Bellmunt, J; Loriot, Y; Necchi, A; Hoffman-Censits, J; Perez-Gracia, J L; van der Heijden, M S; Dreicer, R; Durán, I; Castellano, D; Drakaki, A; Retz, M; Sridhar, S S; Grivas, P; Yu, E Y; O'Donnell, P H; Burris, H A; Mariathasan, S; Shi, Y; Goluboff, E; Bajorin, D
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium

一线联合免疫疗法治疗转移性肾细胞癌患者时，绝对淋巴细胞计数的预后意义：来自国际转移性肾细胞癌数据库联盟的结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103606
Takemura, K; Yuasa, T; Lemelin, A; Ferrier, E; Wells, J C; Saad, E; Saliby, R M; Basappa, N S; Wood, L A; Jude, E; Pal, S K; Donskov, F; Beuselinck, B; Szabados, B; Powles, T; McKay, R R; Gebrael, G; Agarwal, N; Choueiri, T K; Heng, D Y C
肿瘤
肿瘤免疫
肾癌
细胞生物学
免疫/内分泌
发表日期：2024
文献求助 收藏